MedTrace Logo

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

NCT06365970 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-02-03

No results posted yet for this study

Summary

The second line of therapy for patients with MSI-H CRC who experience disease progression on anti-PD1 based therapies is not well defined and there is an unmet need for research for patients with anti-PD1 refractory MSI-H CRC. This study will examine the combination of niraparib and dostarlimab for a synergistic antitumor effect for patients with MSI-H CRC.

Conditions

  • MMR-D/MSI-H Colorectal Cancers

Interventions

DRUG

Niraparib

An anti-cancer medication that helps to repair DNA when it becomes damaged, known as a PARP inhibitor.

DRUG

Dostarlimab

An anti-cancer medication that is a programmed death receptor-1 -blocking monoclonal antibody.

Sponsors & Collaborators

Principal Investigators

  • Ibrahim H Sahin, MD · UPMC Hillman Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-31
Primary Completion
2027-01-31
Completion
2028-01-31
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06365970 on ClinicalTrials.gov